BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li Q, Dong Y, Pan Y, Tang H, Li D. Case Report: Clinical Responses to Tislelizumab as a First-Line Therapy for Primary Hepatocellular Carcinoma With B-Cell Indolent Lymphoma. Front Immunol 2021;12:634559. [PMID: 33868256 DOI: 10.3389/fimmu.2021.634559] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Liu HT, Jiang MJ, Deng ZJ, Li L, Huang JL, Liu ZX, Li LQ, Zhong JH. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges. Front Oncol 2021;11:737497. [PMID: 34745958 DOI: 10.3389/fonc.2021.737497] [Reference Citation Analysis]